Epizyme, Inc. (EPZM) reported that an Independent Data Monitoring Committee had convened earlier this week to assess the futility of its lead candidate tazemetostat for the treatment of follicular lymphoma.
Exelixis, Inc. (EXEL) announced the outcome from the first planned interim analysis of a randomized phase III trial, CELESTIAL, on cabozantinib.
Shares of Dynavax Technologies Corporation (DVAX) bounced back after the company indicated that the FDA will review its BLA for experimental hepatitis B vaccine, Heplisav on the current Prescription Drug User Fee Act (PDUFA) date of Dec 15, 2016.
HCA Holdings Inc. (HCA) recently inked a deal to buy Mobile Heartbeat for an undisclosed amount.
One company that might be well-positioned for future earnings growth is Actelion Ltd. (ALIOF)
Pfizer, Inc. (PFE) announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission (EC).
Array BioPharma (ARRY) presented positive results from a phase II study on its pipeline candidate, ARRY-797, at the European Society of Cardiology Congress 2016 in Rome, Italy.
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
Amgen announced positive data on Prolia and Repatha from late stage studies.
Abbott Labs (ABT) was sued by Alere (ALR) in the latter's attempt to force the former to complete the $5.8 billion takeover.
On Aug 25, 2016, we issued an updated research report on Illumina Inc. (ILMN).
Shares of Vanda Pharmaceuticals (VNDA) surged 20.6% after the U.S. District of Delaware ruled in favor of the company in a patent infringement lawsuit against Roxane Laboratories
Amgen (AMGN) announced that the FDA has issued a Complete Response Letter from for its New Drug Application (NDA) for Parsabiv.
Pfizer (PFE) entered into an agreement to acquire the rights to AstraZeneca's (AZN) late-stage small-molecule anti-infectives business in the ex-U.S. markets.
The FDA will respond on the approval status of rucaparib by Feb 23, 2017.
Galapagos (GLPG) announced the initiation of a phase III program on filgotinib for the treatment of patients with rheumatoid arthritis.
Puma (PBYI) announced that its Marketing Authorization Application for neratinib has been validated by the European Medicines Agency.
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.